|
<PAGE>
Exhibit 10.7
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisk denote
omissions.
AMENDMENT NO. 3 RELATING TO
SPONSORED RESEARCH AND LICENSE AGREEMENT
BETWEEN
CRITICAL THERAPEUTICS, INC.
AND
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
DATED JANUARY 1, 2003
THIS AMENDMENT NO. 3 is made the 29th day of June, 2007.
BETWEEN:
(1) CRITICAL THERAPEUTICS, INC., a Delaware corporation ("CTI");
and
(2) THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH, a New York
not-for-profit
corporation ("FEINSTEIN")
RECITALS:
(A) CTI and Feinstein entered into a Sponsored Research and
License
Agreement, dated January 1, 2003.
(B) The said Sponsored Research and License Agreement was
modified by that
certain Letter Agreement between CTI and Feinstein dated
February 3,
2004, and was amended by each of Amendment No. 1 dated September
18,
2006 and Amendment No. 2 dated January 8, 2007. The Sponsored
Research
and License Agreement as so modified and so amended is referred
to
herein as the "ORIGINAL AGREEMENT".
(C) CTI and Feinstein have agreed to amend the Original
Agreement by and
upon the terms of this Amendment No. 3.
OPERATIVE PROVISIONS:
1. INTRODUCTION, DEFINITIONS AND INTERPRETATION
1.1. This Amendment No. 3 is supplemental to the Original
Agreement.
1.2. In this Amendment, the expression "THIS AMENDMENT NO. 3"
shall mean this
Amendment No. 3, including its recitals and schedules.
1.3 Except where expressly provided to the contrary in this
Amendment No. 3:
1.3.1 all capitalized terms used in this Amendment No. 3 shall
have the
same meanings as are assigned thereto in the Original Agreement,
as
amended by this Amendment No. 3; and
<PAGE>
1.3.2 this Amendment No. 3 shall be interpreted in the same
manner as the
Original Agreement.
1.4 Re
| 
